Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Life-threatening hypothyroidism associated with administration of cyclosporine in a patient treated with reduced-intensity hematopoietic stem-cell transplantation for metastatic renal-cell carcinoma.
Imataki O, Kim SW, Kojima R, Hori A, Hamaki T, Sakiyama M, Murashige N, Satoh M, Kami M, Makimoto A, Takaue Y. Imataki O, et al. Among authors: murashige n. Transplantation. 2003 Mar 27;75(6):898-907. doi: 10.1097/01.TP.0000055048.16538.4E. Transplantation. 2003. PMID: 12660521 No abstract available.
Induction of graft-versus-autoimmune (GVA) disease effect against refractory psoriasis by complete donor-type chimerism and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Kojima R, Kami M, Kim SW, Murashige N, Kishi Y, Hori A, Imataki O, Hamaki T, Sakiyama M, Masuo S, Fujisawa Y, Makimoto A, Heike Y, Tanosaki R, Takaue Y. Kojima R, et al. Among authors: murashige n. Bone Marrow Transplant. 2003 Aug;32(4):439-42. doi: 10.1038/sj.bmt.1704146. Bone Marrow Transplant. 2003. PMID: 12900783
Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor.
Kusumi E, Kami M, Yuji K, Hamaki T, Murashige N, Hori A, Kojima R, Kishi Y, Kim SW, Ueyama J, Miyakoshi S, Tanosaki R, Morinaga S, Mori S, Heike Y, Muto Y, Masuo S, Taniguchi S, Takaue Y. Kusumi E, et al. Among authors: murashige n. Bone Marrow Transplant. 2004 Apr;33(7):697-702. doi: 10.1038/sj.bmt.1704425. Bone Marrow Transplant. 2004. PMID: 14755317
Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies.
Hamaki T, Kami M, Kim SW, Onishi Y, Kishi Y, Murashige N, Hori A, Kojima R, Sakiyama M, Imataki O, Heike Y, Tanosaki R, Masuo S, Miyakoshi S, Taniguchi S, Tobinai K, Takaue Y. Hamaki T, et al. Among authors: murashige n. Bone Marrow Transplant. 2004 May;33(9):891-900. doi: 10.1038/sj.bmt.1704477. Bone Marrow Transplant. 2004. PMID: 15048142 Clinical Trial.
Regimen-related toxicity following reduced-intensity stem-cell transplantation (RIST): comparison between Seattle criteria and National Cancer Center Common Toxicity Criteria (NCI-CTC) version 2.0.
Sakiyama M, Kami M, Hori A, Imataki O, Hamaki T, Murashige N, Kobayashi K, Kishi Y, Kojima R, Kim SW, Kusumi E, Yuji K, Miyakoshi S, Mori S, Tanosaki R, Taniguchi S, Takaue Y; Tokyo SCT Consortium. Sakiyama M, et al. Among authors: murashige n. Bone Marrow Transplant. 2004 Nov;34(9):787-94. doi: 10.1038/sj.bmt.1704673. Bone Marrow Transplant. 2004. PMID: 15361909
Value of surveillance blood culture for early diagnosis of occult bacteremia in patients on corticosteroid therapy following allogeneic hematopoietic stem cell transplantation.
Chizuka A, Kami M, Kanda Y, Murashige N, Kishi Y, Hamaki T, Kim SW, Hori A, Kojima R, Mori SI, Tanosaki R, Gomi H, Takaue Y. Chizuka A, et al. Among authors: murashige n. Bone Marrow Transplant. 2005 Mar;35(6):577-82. doi: 10.1038/sj.bmt.1704830. Bone Marrow Transplant. 2005. PMID: 15665840
Optimal initial dose of oral cyclosporine in relation to its toxicities for graft-versus-host disease prophylaxis following reduced-intensity stem cell transplantation in Japanese patients.
Kishi Y, Murashige N, Kami M, Miyakoshi S, Shibagaki Y, Hamaki T, Takaue Y, Taniguchi S; Tokyo Stem Cell Transplantation (SCT) Consortium. Kishi Y, et al. Among authors: murashige n. Bone Marrow Transplant. 2005 Jun;35(11):1079-82. doi: 10.1038/sj.bmt.1704960. Bone Marrow Transplant. 2005. PMID: 15806118
Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation.
Hori A, Kami M, Kim SW, Chizuka A, Kojima R, Imataki O, Sakiyama M, Hamaki T, Onishi Y, Usubuchi N, Kishi Y, Murashige N, Tajima K, Miyakoshi S, Heike Y, Masuo S, Taniguchi S, Takaue Y. Hori A, et al. Among authors: murashige n. Biol Blood Marrow Transplant. 2004 Jan;10(1):65-72. doi: 10.1016/j.bbmt.2003.09.006. Biol Blood Marrow Transplant. 2004. PMID: 14752781 Free article.
Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up.
Nakagawa T, Kami M, Hori A, Kim SW, Murashige N, Hamaki T, Kishi Y, Fujimoto H, Matsuoka N, Okajima E, Komiyama M, Tobisu K, Wakayama T, Uike N, Tajima K, Makimoto A, Mori S, Tanosaki R, Takaue Y, Kakizoe T. Nakagawa T, et al. Among authors: murashige n. Exp Hematol. 2004 Jul;32(7):599-606. doi: 10.1016/j.exphem.2004.04.006. Exp Hematol. 2004. PMID: 15246155 Free article.
93 results